Please assess the completion status of the following clinical trial:

Trial Title: Flexitouch Treatment for Venous Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be at least 18 years old~2. The ulcer maximum length x its maximum width must be greater or equal to 0 cm2~3. The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.~4. The ulcer must have been present for more than 1 month.~5. The ulcer must be located below the knee.~6. The ulcer bed must have some viable tissues with some granulation tissue.~Exclusion Criteria:~1. Exposed bone, tendon, or fascia~2. Severe rheumatoid arthritis~3. History of radiotherapy to the ulcer site~4. Uncontrolled congestive heart failure~5. Receiving corticosteroids or immune suppressive therapy~6. History of collagen vascular disease~7. Known malnutrition (albumin\<3.0 g/dL). If malnutrition is suspected, the albumin level should be checked to determine if the patient meets the albumin criterion.~8. The ulcer is clinically infected. However, patients may be entered into the study after successful treatment of infection.~9. Known uncontrolled diabetes (HgbA1c \> 8%). If uncontrolled diabetes is suspected, the Hgb A1c should be checked to determine patient eligibility.~10. Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).~11. Known arterial insufficiency (Ankle-brachial index \< 0.7, or TcPO2 \< 35 mm Hg, or Toe-brachial index \< 0.4). If peripheral vascular disease is suspected, vascular lab testing should be checked to determine patient eligibility.~12. Active sickle cell disease~13. Unable to comply with the procedures described in the protocol~14. Enrolled in a clinical evaluation for another investigational wound-care device or drug~15. Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months~16. Pregnancy, suspected or confirmed~17. Chronic renal disease, if deemed by the principal investigator to be severe enough to interfere with wound healing~18. Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy~19. History or pulmonary embolism~20. Poorly controlled asthma~21. Pulmonary Edema

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Wound Care (Type: ACTIVE_COMPARATOR): Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
- Flexitouch system with Standard Wound Care (Type: ACTIVE_COMPARATOR): In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues